


Listing of Claims

1. (Currently Amended) A compound of the formula I:



I

wherein:

R¹ is selected from the group consisting of:

- (1) -C₁₋₆alkyl,
- (2) -C₂₋₆ alkenyl,
- (3) -C₂₋₆ alkynyl,

wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with phenyl, which is unsubstituted or substituted with a group selected from:

- (i) halo,
 - (ii) -C₁₋₆alkyl,
 - (iii) -C₂₋₆ alkenyl,
 - (iv) -C₂₋₆ alkynyl,
 - (v) -OH, and
 - (vi) -O-C₁₋₆alkyl,
- (4) hydrogen;

R² is selected from the group consisting of:

- (1) R⁴-S(O)₂N(R⁷)-,

wherein R⁴ is independently selected from the group consisting of:

- (a) -C₁₋₆alkyl,
- (b) -C₂₋₆ alkenyl,
- (c) -C₂₋₆ alkynyl,

wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with ~~1-6 fluoro~~ one to six fluoros,

(d) phenyl, and

(e) benzyl,

wherein R^7 is independently selected from the group consisting of:


(a) hydrogen,

(b) -C₁₋₆alkyl,

(c) -C₂₋₆ alkenyl,

(d) -C₂₋₆ alkynyl,

(2)



wherein R^{8a} and R^{8b} are independently selected from the group consisting of:

(a) hydrogen,

(b) -CN,


(c) halo,

(d) -C₁₋₆alkyl,

(e) -C₂₋₆ alkenyl, and

(f) -C₂₋₆ alkynyl

R^3 is selected from the group consisting of:



R^{6a} , R^{6b} , and R^{6c} are independently selected from the group consisting of:

(1) hydrogen, and

(2) halogen;

R⁵ is selected from the group consisting of:

- (1) -C₁₋₆alkyl,
- (2) -C₂₋₆ alkenyl,
- (3) -C₂₋₆ alkynyl,

wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with phenyl, and

- (4) hydrogen;

R¹³ is selected from the group consisting of -CH=CH- and -O-;

R⁹ and R¹⁰ are independently selected from the group consisting of:

- (1) hydrogen,
- (2) C₁₋₆alkyl,
- (3) C₂₋₆ alkenyl,
- (4) C₂₋₆ alkynyl, wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with phenyl,

or R⁹ and R¹⁰ may be joined together to form a pyrrolidine or piperidine ring which is unsubstituted or substituted with -C₁₋₆alkyl, -C₂₋₆ alkenyl, -C₂₋₆ alkynyl, -C₁₋₆alkyl-O-C₁₋₆alkyl, phenyl or pyridyl;

R¹¹ is selected from the group consisting of:

- (1) -OH,
- (2) -O-C₁₋₆alkyl,
- (3) -O-C₁₋₆alkyl-phenyl,
- (4) -O-phenyl, and
- (5) phenyl;


R¹² is selected from the group consisting of:

- (1) -NR⁹R¹⁰, and
- (2) -OH;

m is independently 0, 1, or 2;

and pharmaceutically acceptable salts thereof.

2. (Original) The compound of Claim 1 of the formula II:



II

wherein:

R¹ is selected from the group consisting of:

- (1) C₁-6alkyl, unsubstituted or substituted with phenyl, and
- (2) hydrogen;

R² is selected from the group consisting of:

- (1) R⁴-S(O)₂N(R⁷)-,


wherein R⁴ is independently selected from the group consisting of:

- (a) C₁-6alkyl, which is unsubstituted or substituted with 1-6 fluoro,
- (b) phenyl, and
- (c) benzyl,

wherein R⁷ is independently selected from the group consisting of:

- (a) hydrogen, and
- (b) -C₁-6alkyl,

(2)



wherein R^{8a} and R^{8b} are independently selected from the group consisting of:

- (a) hydrogen,
- (b) -CN,
- (c) halo, and
- (d) -C₁-6alkyl,

R⁵ is selected from the group consisting of:

- (1) C₁₋₆alkyl, unsubstituted or substituted with phenyl, and
- (2) hydrogen;


R⁹ and R¹⁰ are independently selected from the group consisting of:

- (1) hydrogen, and
- (2) C₁₋₆alkyl, unsubstituted or substituted with phenyl;

R¹¹ is selected from the group consisting of:

- (1) -OH,
- (2) -O-phenyl, and
- (3) phenyl.

3. (Original) The compound of Claim 1 of the formula III:



III

wherein:

R¹ is selected from the group consisting of:

- (1) C₁₋₆alkyl, unsubstituted or substituted with phenyl, and
- (2) hydrogen;

R² is selected from the group consisting of:

- (1) R⁴-S(O)₂N(R⁷)-,

wherein R⁴ is independently selected from the group consisting of:

- (a) C₁₋₆alkyl, which is unsubstituted or substituted with 1-6 fluoro,
- (b) phenyl, and


(c) benzyl,

wherein R^7 is independently selected from the group consisting of:

(a) hydrogen, and

(b) $-C_{1-6}$ alkyl,

(2)



wherein R^{8a} and R^{8b} are independently selected from the group consisting of:

(a) hydrogen,

(b) $-CN$,

(c) halo, and

(d) $-C_{1-6}$ alkyl,

R^5 is selected from the group consisting of:

(1) C_{1-6} alkyl, unsubstituted or substituted with phenyl, and

(2) hydrogen;

R^{11} is selected from the group consisting of:

(1) $-OH$,

(2) $-O$ -phenyl, and

(3) phenyl.

4. (Original) The compound of Claim 1 wherein R^1 is selected from the group consisting of:

(1) benzyl,

(2) phenyl-ethyl-,

(3) methyl, and

(4) hydrogen.

5. (Original) The compound of Claim 1 wherein R^2 is $CH_3-S(O)_2N(CH_3)-$.

6. (Original) The compound of Claim 1 wherein R^2 is cyano-phenyl-.


7. (Original) The compound of Claim 1 wherein R⁵ is methyl.


8. (Original) The compound of Claim 1 wherein R⁹ and R¹⁰ are independently selected from the group consisting of:


- (1) hydrogen, and
- (2) methyl.

9. (Original) The compound of Claim 1 wherein R¹¹ is -OH.

10. (Original) A compound which is selected from the group consisting of:







and pharmaceutically acceptable salts thereof.

11. (Original) A pharmaceutical composition comprising an effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. (Original) A method for inhibition of beta-secretase activity in a mammal in need thereof which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

13. (Original) A method for treating Alzheimer's disease in a patient in need thereof comprising administering to the patient an effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

14. (Canceled)